Breaking News Instant updates and real-time market news.

AERI

Aerie Pharmaceuticals

$55.50

1.3 (2.40%)

06:32
07/31/17
07/31
06:32
07/31/17
06:32

Aerie Pharmaceuticals enters research collaboration agreement with DSM

Aerie Pharmaceuticals announced that it has entered into a collaborative research, development and license agreement with DSM. The research collaboration agreement includes an option to license DSM's bioerodible polymer implant technology for evaluating its application to the delivery of certain Aerie compounds, initially focused on retinal diseases. DSM's technology uses polyesteramide polymers (PEA) to produce an injectable, thin fiber that is minute in size. Preclinical experiments have demonstrated early success in conjunction with Aerie compounds, including demonstration of linear sustained elution rates over several months and achievement of target retinal drug concentrations. Aerie previously reported data on Aerie-owned small molecule preclinical product candidate AR-13154, which inhibits Rho kinase and Protein kinase C and thus addresses vascular dysfunction, fibrosis, and inflammation. This molecule has generated lesion size decreases in a preclinical model of wet AMD at levels similar to the market-leading wet AMD anti-VEGF product, and has generated meaningful incremental lesion size reduction when added adjunctively to the anti-VEGF product. Preclinical studies also demonstrated the promising potential of this molecule to reduce neovascularization in a model of proliferative diabetic retinopathy. Pending additional studies, AR-13154 and related compounds may have the potential to provide an entirely new mechanism and pathway to treat these diseases. The terms of the agreement with DSM were not disclosed and the agreement is immaterial to Aerie based on the level of current financial commitments.

  • 28

    Feb

AERI Aerie Pharmaceuticals
$55.50

1.3 (2.40%)

04/13/17
HCWC
04/13/17
NO CHANGE
Target $42
HCWC
Buy
Aerie pullback on hyperemia increase an overreaction, says H.C. Wainwright
H.C. Wainwright analyst Corey Davis said despite the "positive" safety and efficacy data Aerie Pharmaceuticals' reported from its trial of Rhopressa, "focus for the Street" was clearly on the 48% hyperemia rate and 31% discontinuation rate. However, the rate of events outside of hyperemia is relatively comparable to that seen with approved products Lumigan and Travatan and mild redness is likely of little real-world concern in a condition as serious as glaucoma, he tells investors. The analyst, who sees the first-read response in the shares as an overreaction, has a Buy rating and $69 price target on Aerie shares, which are down about 1% to $42 in pre-market trading after suffering a sharper decline in after-market trading last night.
05/25/17
COWN
05/25/17
NO CHANGE
Target $100
COWN
Outperform
Aerie Pharmaceuticals probability of a takeout increasing, says Cowen
Cowen analyst Tyler Van Buren noted the Aerie Pharmaceuticals Roclatan trial was successful and appears approvable as the first FDA approved prostaglandin product. He also noted its Rhopressa drug which is also under review appears approvable as well and combined, the drugs represent a $1.5B long duration opportunity. The analyst believes Aerie is a prime consolidation candidate and said it is not unreasonable to put a 4x multiple on peak sales of $1.5B arrives at a $130-$140 per shares valuation. Van Buren reiterated his Outperform rating and raised his price target to $100 from $70 on Aerie Pharmaceuticals shares.
05/25/17
NEED
05/25/17
NO CHANGE
Target $65
NEED
Buy
Aerie Pharmaceuticals price target raised to $65 from $58 at Needham
Needham analyst Serge Belanger raised his price target for Aerie Pharmaceuticals to $65 saying the company reported positive results from Mercury-2, the second of two Phase 3 trials evaluating Roclatan as treatment for glaucoma. Once again, Roclatan met all its endpoints, Belanger tells investors in a research note. The data are a "key derisking event" for the program, the analyst adds. He keeps a Buy rating on Aerie.
07/03/17
ADAM
07/03/17
NO CHANGE
Target $65
ADAM
Buy
Aerie price target raised to $65 from $60 at Canaccord
Canaccord analyst Dewey Steadman said he remains confident in Aerie Pharmaceuticals' ability to launch Rhopressa as early at the first half of next year, noting that the company is preparing for an FDA advisory committee meeting that could happen before Thanksgiving. Steadman, who sees Rhopressa as a $500M product at its peak, also said he's confident in a potential Roclatan approval in 2019, stating that could be a $1B product. The analyst keeps a Buy rating on Aerie shares and raised his price target on the stock to $65 from $60.

TODAY'S FREE FLY STORIES

FL

Foot Locker

$47.70

-0.87 (-1.79%)

06:49
08/18/17
08/18
06:49
08/18/17
06:49
Earnings
Foot Locker reports Q2 EPS ex-items 62c, consensus 90c »

Reports Q2 revenue $1.7B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

EL

Estee Lauder

$98.32

-2.75 (-2.72%)

06:48
08/18/17
08/18
06:48
08/18/17
06:48
Earnings
Estee Lauder sees FY18 adjusted EPS $3.87-$3.94, consensus $3.79 »

FY18 net sales are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

CPN

Calpine

$13.50

-0.42 (-3.02%)

06:48
08/18/17
08/18
06:48
08/18/17
06:48
Hot Stocks
Calpine: Transaction the result of 'exhaustive' review of strategic alternatives »

"We are very pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPN

Calpine

$13.50

-0.42 (-3.02%)

06:47
08/18/17
08/18
06:47
08/18/17
06:47
Hot Stocks
Calpine to be acquired by ECP, consortium for $15.25 per share, or $5.6B »

Calpine Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:47
08/18/17
08/18
06:47
08/18/17
06:47
General news
Futures stable following yesterday's selloff »

US equity futures are…

EL

Estee Lauder

$98.32

-2.75 (-2.72%)

06:46
08/18/17
08/18
06:46
08/18/17
06:46
Earnings
Estee Lauder sees FY18 revenue growth 7%-8%, consensus $12.6B »

CEO Freda continued,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

CPN

Calpine

$13.50

-0.42 (-3.02%)

06:45
08/18/17
08/18
06:45
08/18/17
06:45
Hot Stocks
Breaking Hot Stocks news story on Calpine »

Calpine to be acquired by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$98.32

-2.75 (-2.72%)

06:45
08/18/17
08/18
06:45
08/18/17
06:45
Earnings
Estee Lauder reports Q4 adjusted EPS 51c, consensus 43c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

06:45
08/18/17
08/18
06:45
08/18/17
06:45
General news
FX Action: The dollar has lifted from lows »

FX Action: The dollar…

KO

Coca-Cola

$45.86

-0.34 (-0.74%)

, PEP

PepsiCo

$118.39

-0.71 (-0.60%)

06:44
08/18/17
08/18
06:44
08/18/17
06:44
Periodicals
Coca-Cola to replace PepsiCo as Arby's beverage supplier, Bloomberg says »

Coca-Cola (KO) will…

KO

Coca-Cola

$45.86

-0.34 (-0.74%)

PEP

PepsiCo

$118.39

-0.71 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

URI

United Rentals

$111.82

-0.15 (-0.13%)

06:42
08/18/17
08/18
06:42
08/18/17
06:42
Upgrade
United Rentals rating change  »

United Rentals upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

DE

Deere

$123.98

-2.65 (-2.09%)

06:40
08/18/17
08/18
06:40
08/18/17
06:40
Earnings
Deere raises FY17 net sales and revenue guidance to up 11% from up 9% »

Company equipment sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Nov

PNM

PNM Resources

$41.70

-0.3 (-0.71%)

06:39
08/18/17
08/18
06:39
08/18/17
06:39
Downgrade
PNM Resources rating change  »

PNM Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$105.92

-0.92 (-0.86%)

06:38
08/18/17
08/18
06:38
08/18/17
06:38
Periodicals
Chevron withdraws appeal of Australian tax bill, Reuters says »

Chevron has decided to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Sep

LB

L Brands

$37.55

-1.4 (-3.59%)

06:38
08/18/17
08/18
06:38
08/18/17
06:38
Recommendations
L Brands analyst commentary  »

L Brands dividend yield…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$123.98

-2.65 (-2.09%)

06:36
08/18/17
08/18
06:36
08/18/17
06:36
Earnings
Breaking Earnings news story on Deere »

Deere raises FY17 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Nov

HSY

Hershey

$107.85

1.81 (1.71%)

06:35
08/18/17
08/18
06:35
08/18/17
06:35
Recommendations
Hershey analyst commentary  »

Citi says Hershey…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIBB

Hibbett Sports

$11.50

-0.3 (-2.54%)

06:34
08/18/17
08/18
06:34
08/18/17
06:34
Hot Stocks
Hibbett Sports sees 'continued soft sales' for remainder of FY18 »

The company is updating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

RAVN

Raven

$33.45

-0.975 (-2.83%)

06:34
08/18/17
08/18
06:34
08/18/17
06:34
Initiation
Raven initiated  »

Raven initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

PACW

PacWest Bancorp

$44.13

-1.63 (-3.56%)

06:34
08/18/17
08/18
06:34
08/18/17
06:34
Initiation
PacWest Bancorp initiated  »

PacWest Bancorp initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATY

Cathay General

$34.97

-0.94 (-2.62%)

06:34
08/18/17
08/18
06:34
08/18/17
06:34
Initiation
Cathay General initiated  »

Cathay General initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIBB

Hibbett Sports

$11.50

-0.3 (-2.54%)

06:33
08/18/17
08/18
06:33
08/18/17
06:33
Hot Stocks
Hibbett Sports CEO says 'experienced a very difficult retail environment' in Q2 »

Jeff Rosenthal, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

DE

Deere

$123.98

-2.65 (-2.09%)

06:33
08/18/17
08/18
06:33
08/18/17
06:33
Earnings
Deere reports Q3 EPS $1.97, consensus $1.95 »

Reports Q3 net sales and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 22

    Nov

HIBB

Hibbett Sports

$11.50

-0.3 (-2.54%)

06:32
08/18/17
08/18
06:32
08/18/17
06:32
Earnings
Hibbett Sports cuts FY18 EPS view to $1.25-$1.35 from $2.35-$2.55 »

FY18 consensus $1.74.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

PM

Philip Morris

$115.93

-1.8 (-1.53%)

06:32
08/18/17
08/18
06:32
08/18/17
06:32
Periodicals
India threatens Philip Morris with 'punitive action', Reuters reports »

India's federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.